Insulin Makers May Be First In Crosshairs Of DeGette Rx Pricing Investigation
Rep. Diana DeGette, new chair of US House Energy and Commerce Committee's Subcommittee on Oversight and Investigations, said insulin is a good example of problems with drug pricing and promised to call drug company CEOs to hearings.
You may also be interested in...
Executives from Eli Lilly, Novo Nordisk and Sanofi, as well as representatives from the three largest pharmacy benefit managers, will testify before the House Energy and Commerce Committee’s Subcommittee on Oversight and Investigations April 10; patients, professional organization representatives and academics at an April 2 hearing said they want to know why insulin prices remain out of reach for many diabetics.
Letters to Lilly, Novo Nordisk and Sanofi signal potential next avenue for Finance Committee's investigation after CEO hearing on Tuesday.
In State of the Department speech and HHS annual report, Secretary Azar trumpets historic number of approvals by FDA, and price cuts, roll backs or freezes by 'more than a dozen drug companies.'